These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22995933)

  • 41. Antipsychotic treatment response in schizophrenia.
    Gardner KN; Bostwick JR
    Am J Health Syst Pharm; 2012 Nov; 69(21):1872-9. PubMed ID: 23111671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study.
    Tsuboi T; Suzuki T; Bies RR; Remington G; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2015 May; 164(1-3):149-54. PubMed ID: 25864950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
    Levine SZ; Leucht S
    Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year.
    Sanz-Fuentenebro J; Taboada D; Palomo T; Aragües M; Ovejero S; Del Alamo C; Molina V
    Schizophr Res; 2013 Sep; 149(1-3):156-61. PubMed ID: 23870807
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Attaining and sustaining remission of predominant negative symptoms.
    Levine SZ; Leucht S
    Schizophr Res; 2013 Jan; 143(1):60-4. PubMed ID: 23218563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii.
    Wang HL; Xiang YT; Li QY; Wang XP; Liu ZC; Hao SS; Liu X; Liu LL; Wang GH; Wang DG; Zhang PA; Bao AY; Chiu HF; Ungvari GS; Lai KY; Buchanan RW
    J Psychiatr Res; 2014 Jun; 53():119-24. PubMed ID: 24656425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.
    Moritz S; Veckenstedt R; Andreou C; Bohn F; Hottenrott B; Leighton L; Köther U; Woodward TS; Treszl A; Menon M; Schneider BC; Pfueller U; Roesch-Ely D
    JAMA Psychiatry; 2014 Oct; 71(10):1103-11. PubMed ID: 25103718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prefrontal lobe dysfunction predicts treatment response in medication-naive first-episode schizophrenia.
    van Veelen NM; Vink M; Ramsey NF; van Buuren M; Hoogendam JM; Kahn RS
    Schizophr Res; 2011 Jul; 129(2-3):156-62. PubMed ID: 21497488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic Response Is Associated With Antipsychotic-Induced Weight Gain in Drug-Naive First-Episode Patients With Schizophrenia: An 8-Week Prospective Study.
    Chen YQ; Li XR; Zhang L; Zhu WB; Wu YQ; Guan XN; Xiu MH; Zhang XY
    J Clin Psychiatry; 2021 May; 82(3):. PubMed ID: 34004092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia.
    Tang H; Dalton CF; Srisawat U; Zhang ZJ; Reynolds GP
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):645-9. PubMed ID: 24331356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The association between weight change and symptom reduction in the CATIE schizophrenia trial.
    Hermes E; Nasrallah H; Davis V; Meyer J; McEvoy J; Goff D; Davis S; Stroup TS; Swartz M; Lieberman J; Rosenheck R
    Schizophr Res; 2011 May; 128(1-3):166-70. PubMed ID: 21334853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
    Hopkins SC; Ogirala A; Loebel A; Koblan KS
    Schizophr Bull; 2018 Apr; 44(3):593-602. PubMed ID: 28981857
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do we need oxytocin to treat schizophrenia? A randomized clinical trial.
    Dagani J; Sisti D; Abelli M; Di Paolo L; Pini S; Raimondi S; Rocchi MB; Saviotti FM; Scocco P; Totaro S; Balestrieri M; de Girolamo G
    Schizophr Res; 2016 Apr; 172(1-3):158-64. PubMed ID: 26883950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response trajectories in "real-world" naturalistically treated schizophrenia patients.
    Schennach R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Musil R; Möller HJ; Riedel M
    Schizophr Res; 2012 Aug; 139(1-3):218-24. PubMed ID: 22658528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia.
    Stefanović V; Mihajlović G; Nenadović M; Dejanović SD; Borovcanin M; Trajković G
    Vojnosanit Pregl; 2015 Dec; 72(12):1085-92. PubMed ID: 26898032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Damaging Rare Mutations in Synapse-Related Gene Sets on Response to Short-term Antipsychotic Medication in Chinese Patients With Schizophrenia: A Randomized Clinical Trial.
    Wang Q; Man Wu H; Yue W; Yan H; Zhang Y; Tan L; Deng W; Chen Q; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Yang F; Li L; Wang C; Ma X; Zhao L; Ren H; Yu H; Wang Y; Hu X; Zhang D; Sham P; Li T;
    JAMA Psychiatry; 2018 Dec; 75(12):1261-1269. PubMed ID: 30422257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial.
    Schulz M; Gray R; Spiekermann A; Abderhalden C; Behrens J; Driessen M
    Schizophr Res; 2013 May; 146(1-3):59-63. PubMed ID: 23452506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.